Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. Issue 6 (14th October 2016)

• Record Type: Journal Article
• Authors: Schelle, Juliane; Häsler, Lisa M.; Göpfert, Jens C.; Joos, Thomas O.; Vanderstichele, Hugo; Stoops, Erik; Mandelkow, Eva‐Maria; Neumann, Ulf; Shimshek, Derya R.; Staufenbiel, Matthias; Jucker, Mathias; Kaeser, Stephan A.
• Is Part Of: Alzheimer's & dementia. Volume 13:Issue 6(2017)
• Page Start: 701
• Page End: 709
• Publication Date: 2016-10-14
• Subjects: Alzheimer's disease -- Biomarker -- CSF -- Tau -- BACE1 inhibitor -- Treatment; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1016/j.jalz.2016.09.005
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Introduction: The inhibition of the β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) is a main therapeutic approach for the treatment of Alzheimer's disease (AD). We previously reported an age‐related increase of tau protein in the cerebrospinal fluid (CSF) of amyloid β (Aβ) precursor protein (APP) transgenic mice. Methods: APP transgenic mice were treated with a potent BACE1 inhibitor. CSF tau and CSF Aβ levels were assessed. A novel high‐sensitivity tau sandwich immunoassay was developed. Results: We demonstrate that long‐term BACE1 inhibition prevents CSF tau increase both in early‐depositing APP transgenic mice and APP transgenic mice with moderate Aβ pathology. Discussion: Our results demonstrate that BACE1 inhibition not only reduces Aβ generation but also downstream AD pathophysiology. The tight correlation between Aβ aggregation in brain and CSF tau levels renders CSF tau a valuable marker to predict the effectiveness of BACE1 inhibitors in current clinical trials.